| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
As a linker, Ald-Ph-PEG4-NHS ester does not have a biological target. Its function is to connect a molecule containing an amine (e.g., a protein or peptide) to a molecule containing an aldehyde-reactive group (e.g., a drug with a hydrazide). It is widely used in PROTAC synthesis, ADC development, and labeling of proteins for imaging or drug delivery.
|
|---|---|
| ln Vitro |
In vitro, Ald-Ph-PEG4-NHS ester is used to synthesize bioconjugates. The NHS ester reacts rapidly with amines at pH 7-9, forming a stable amide bond. The aldehyde can be later conjugated to hydrazines or aminooxy groups. The PEG spacer reduces steric hindrance and improves solubility. Conjugation efficiency is confirmed by SDS-PAGE, HPLC, or mass spectrometry.
|
| ln Vivo |
In vivo applications are through the conjugates made with this linker. The PEG4 spacer influences the stability and pharmacokinetics of the conjugate. The aldehyde provides an orthogonal handle for further modification or for reversible crosslinking. The compound is used in research to create functionalized biomolecules.
|
| Enzyme Assay |
In vitro assays for this linker include testing its reactivity with amine-containing molecules. For example, reaction with a small molecule amine can be monitored by HPLC. The stability of the NHS ester in aqueous buffer is assessed by measuring hydrolysis. These protocols are for research use.
|
| Cell Assay |
In vitro cell-based assays are not performed with the linker alone. The final conjugate's activity is tested in relevant cell lines. For PROTACs, degradation assays; for ADCs, cytotoxicity assays. The linker's impact on cellular uptake can be evaluated.
|
| Animal Protocol |
In vivo animal studies are done with the final conjugate. Xenograft models are used for efficacy studies. The conjugate is administered parenterally, and tumor growth is monitored. Pharmacokinetic studies determine the half-life and biodistribution, which are affected by the PEG linker.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of the linker are not independently relevant. The PEG4 spacer provides a balance of hydrophilicity and flexibility. Storage at -20°C is recommended. Soluble in DMSO and organic solvents.
|
| Toxicity/Toxicokinetics |
The toxicity of this linker is considered low, as it is a standard PEG-based reagent. However, the NHS ester is reactive and may cause irritation. Standard safety precautions should be followed.
|
| Additional Infomation |
Additional information: Ald-Ph-PEG4-NHS ester is a heterobifunctional PEG linker. It is used in bioconjugation and drug delivery. This product is for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C23H30N2O10
|
|---|---|
| Molecular Weight |
494.4917
|
| Exact Mass |
494.19
|
| CAS # |
1353011-74-1
|
| PubChem CID |
60146186
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.552
|
| LogP |
-2.07
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
35
|
| Complexity |
678
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])N([H])C(C1C([H])=C([H])C(C([H])=O)=C([H])C=1[H])=O)=O)N1C(C([H])([H])C([H])([H])C1=O)=O
|
| InChi Key |
QUFDNMPGNAZKHD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H30N2O10/c26-17-18-1-3-19(4-2-18)23(30)24-8-10-32-12-14-34-16-15-33-13-11-31-9-7-22(29)35-25-20(27)5-6-21(25)28/h1-4,17H,5-16H2,(H,24,30)
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[(4-formylbenzoyl)amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0223 mL | 10.1114 mL | 20.2229 mL | |
| 5 mM | 0.4045 mL | 2.0223 mL | 4.0446 mL | |
| 10 mM | 0.2022 mL | 1.0111 mL | 2.0223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
